(NASDAQ: APGE) Apogee Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.96%.
Apogee Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast APGE's revenue for 2027 to be $303,934,026, with the lowest APGE revenue forecast at $303,934,026, and the highest APGE revenue forecast at $303,934,026. On average, 1 Wall Street analysts forecast APGE's revenue for 2028 to be $28,063,241,734, with the lowest APGE revenue forecast at $28,063,241,734, and the highest APGE revenue forecast at $28,063,241,734.
In 2029, APGE is forecast to generate $56,430,417,494 in revenue, with the lowest revenue forecast at $56,430,417,494 and the highest revenue forecast at $56,430,417,494.